Using CDS (Clinical Decision Support) for Quality Initiatives at a Community Hospital



Similar documents
6/19/2012. Update on Venous Thromboembolism Prophylaxis. Disclosure. Learning Objectives. No conflicts of interest to declare

Overview of the TJC/CMS VTE Core Measures

Published 2011 by the American Academy of Orthopaedic Surgeons 6300 North River Road Rosemont, IL AAOS Clinical Practice Guidelines Unit

Venous Thromboembolic Treatment Guidelines

New Oral Anticoagulants. How safe are they outside the trials?

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM

Pulmonary Embolism Treatment Update

DVT/PE Management with Rivaroxaban (Xarelto)

Stroke/VTE Quality Measure Build for Meaningful Use Stage 1

ANTICOAGULATION USE FOR THE PREVENTION AND TREATMENT OF THROMBOEMBOLIC DISEASE

What Does Pregnancy Have to Do With Blood Clots in a Woman s Legs?

ACUTE DVT MANAGEMENT Richard J. DeMasi, MD April 26, 2014

Trust Guideline for Thromboprophylaxis in Trauma and Orthopaedic Inpatients

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto

Hospital Inpatient Quality Reporting (IQR) Program

3/3/2015. Patrick Cobb, MD, FACP March 2015

NJ DSRIP Learning Collaborative

ACCP CLINICAL RESOURCE

NHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS

Inpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach.

New Oral Anticoagulants

To provide an evidenced-based approach to treatment of patients presenting with deep vein thrombosis.

National Guidance and New Protocols

Building a Safe Anticoagulation Program By knowing that Safety is not about numbers, Safety is about an attitude..

CLINICAL QUALITY MEASURES FINALIZED FOR ELIGIBLE HOSPITALS AND CRITICAL ACCESS HOSPITALS BEGINNING WITH FY 2014

The New Complex Patient. of Diabetes Clinical Programming

AT&T Global Network Client for Windows Product Support Matrix January 29, 2015

Antithrombotic Therapy for VTE Disease

National Guidance and New Protocols

Thrombosis and Hemostasis

Antithrombotic Therapy for VTE Disease

DATE: 06 May 2013 CONTEXT AND POLICY ISSUES

Value-Based Purchasing Program Overview. Maida Soghikian, MD Grand Rounds Scripps Green Hospital November 28, 2012

Inpatient Quality Reporting Program

Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2013

*** Drug Safety Alert ***

Venous thromboembolism: reducing the risk. Quick reference guide. Issue date: January 2010

Joseph A. Caprini, MD, MS, FACS, RVT

September 12, Dear Dr. Corrigan:

Use of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia

emeasures Transitions

High Risk Emergency Medicine

NY Medicaid. EHR Incentive Program

XARELTO (rivaroxaban tablets) in Knee and Hip Replacement Surgery

The Centers for Medicare & Medicaid Services (CMS) Acute Care Hospital Fiscal Year (FY) 2018 Quality Improvement Program Measures

UHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient

Uncontrolled when printed. Version 1.1. Acute Sector. Lead Author/Co-ordinator: Mr Simon Barker Consultant Orthopaedic Surgeon Julie Fraser

COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) CHARTERED BANK ADMINISTERED INTEREST RATES - PRIME BUSINESS*

COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) CHARTERED BANK ADMINISTERED INTEREST RATES - PRIME BUSINESS*

Anticoagulation at the end of life. Rhona Maclean

Introduction. Background to this event. Raising awareness 09/11/2015

Clinical practice guideline for the prevention of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to

The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012

Low Molecular Weight Heparin. All Wales Medicines Strategy Group (AWMSG) Recommendations and advice

EDUCATIONAL PLANNING TOOL:

FOI request into compliance of Trust Venous Thromboembolism (VTE) prevention policies with national VTE guidance

The Role of the Newer Anticoagulants

EHR Meaningful Use 2014 (Stage 1 & 2) DR Reporting Strategies

PARTICULAR ASPECTS OF ANTI-THROMBOTIC TREATMENT IN HIP ARTHROPLASTY

To Bridge or Not to Bridge. Periop Anticoagulation Management. Don Weinshenker, MD Ambulatory Care Denver VAMC

#Aim2Innovate. Share session insights and questions socially. UCLA Primary Care Innovation Model 6/13/2015. Mark S. Grossman, MD, MBA, FAAP, FACP

ABSTRACT The American Physical Therapy Association (APTA), in conjunction with the

Antithrombotic therapy

Review of the Stroke and VTE Measure Sets

Advanced Issues in Peri-Operative VTE Prevention

DISCLAIMER ARTHROPLASTY SOCIETY VTE INFORMATION

Position Statement: The Use of VTED Prophylaxis in Foot and Ankle Surgery

Anti-Coagulation Therapies: A Review of Best Practices for Managing Risk

VTE Virtual Learning Series #1: Preventing VTE: Evidence and Execution

Clinical Decision Support to Advance Venous Thromboembolism Prevention

Prescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients

convey the clinical quality measure's title, number, owner/developer and contact

The New Oral Anticoagulants. Yes

Preventing Blood Clots After Hip or Knee Replacement Surgery or Surgery for a Broken Hip. A Review of the Research for Adults

National Provider Call: Hospital Value-Based Purchasing (VBP) Program

Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention

2. Background This indication of rivaroxaban had not previously been considered by the PBAC.

Backgrounder. Current anticoagulant therapies

ABOUT XARELTO CLINICAL STUDIES

Anticoagulation Dosing at UCDMC Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h

Mastering emeasures - Charting a Course To Align Quality And Payment

NIMC VTE Prophylaxis Section Audit and Reporting Tool User Guide

Cost Effectiveness of Apixaban (Eliquis ) for the Prevention of Venous Thromboembolic Events in Adult Patients who have Undergone Elective Total Hip

East Kent Prescribing Group

2.5mg SC daily. INR target mg SC q 12 hr or 40mg daily. 10 mg PO q day (CrCl 30 ml/min). Avoid if < 30 ml/min. 2.

Clinical Study Synopsis

Professional Practice Model Boards. Kelly Hancock, MSN, RN, NE-BC, Executive CNO, CCHS and Chief Nursing Officer, Cleveland Clinic YORN ID: 507

ASHP Therapeutic Position Statement on the Role of Pharmacotherapy in Preventing Venous Thromboembolism in Hospitalized Patients

AnMed Health Disparities Dashboard

Venous Thromboembolism

Case 2:08-cv ABC-E Document 1-4 Filed 04/15/2008 Page 1 of 138. Exhibit 8

Evidence Based Practice to. Value Based Purchasing. Barb Rogness BSN MS Building Bridges May 2013

Transcription:

Using CDS (Clinical Decision Support) for Quality Initiatives at a Community Hospital Jonathan Sykes MD, CMIO Jacalyn Liebowitz RN, MBA,NEA-BCFACHE VP Care Continuum Allegiance Health - Jackson, MI DISCLAIMER: The views and opinions expressed in this presentation are those of the author and do not necessarily represent official policy or position of HIMSS.

Conflict of Interest Disclosure Jonathan Sykes, MD Jacalyn Liebowitz, RN Has no real or apparent conflicts of interest to report. 2013 HIMSS

Learning Objectives Translate lengthy clinical guidelines into CDS that community hospital physicians are likely to accept Recognize how to embed CDS in harmony with physician workflow Employ collaborative (vs. hierarchical) techniques for winning over skeptics Create a repeatable process for designing, deploying, and measuring/ increasing use of multiple CPOE forms tied to various initiatives

CDS Development Process Clinical Problem Identified Collect Pertinent Evidence Clinical Quality Specialist, EBSCO Dynamed Review Evidence With Subject Matter Expert Multidisciplinary Team, Medical Director Create Content and Workflow in CPOE System CMIO, Clinical Informatics Team Inform Medical Executive Committee Deploy and Measure Adoption

Clinical Problem Venous Thromboembolism (VTE) Prevention Hospital Acquired VTE (DVT + PE)* 1 VTE per 1000 persons per year 60% are hospital acquired Occurrence (NO prophylaxis & routine screening) ALL DVT = 10-20%; proximal DVT 4-5% Fatal PE account for 5-10% of in-hospital deaths Other Morbidity Increased hospital length of stay ($10-20K/episode) Risk of anticoagulants, recurrence Post-phlebitic syndrome * DVT = Deep Venous Thrombosis; PE = Pulmonary Embolism

Clinical Evidence- Medical Patients Heparin vs No Treatment (18) LMWH vs. UFH (14) Relative Rate Statistical Significance Relative Rate Statistical Significance Mortality 0.93 No 0.94 No Symptomatic VTE 0.70 No 0.67 Yes Pulmonary Embolism 0.75 Yes All Bleeding 1.28 Yes Major Bleeding 1.61 No 0.95 No 1. Assess risk of thromboembolism and bleeding in medical patients prior to initiation of prophylaxis 2. Use pharmacologic agents unless assessed risk of bleeding outweighs benefit of prophylaxis 3. Do not use graduated compression stockings Venous Thromboembolism Prophylaxis in Hospitalized Patients: A Clinical Practice Guideline From the American College of Physicians, Ann Intern Med 2011; 155:625-632

Clinical Evidence ACCP Guideline Updated in 2012, 9 th Edition; 800+ pages Considered Gold Standard Stricter adherence to Evidence GRADE Included multiple patient types: Non-surgical Surgical, non-orthopedic Surgical, orthopedic Pregnant Neonates and Children Antithrombotic Therapy and Prevention of Thrombosis, 9 th Ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 2012; 141S:1-823

Assessment Pharmacologic Mechanical Population Hospitalized Acutely Ill Medical Patients Hospitalized Critically Ill Patients Patients With Cancer in Outpatient Setting Risk of Thrombosis Incidence Roger's Caprini Risk of Bleeding Increased Y Y N Low N N Active or High N N Y Y N Y Y Active or High N N N Y Y Low N N N Additional Factors Low Y Y Central Venous Catheter N N N Chronically Immobilized Patients N N Long Distance Travel Increased N N N Y Assymptomatic Person With Thrombophilia N N General and Abdominal-Pelvic Surgery Very Low <0.5% <7 0 N N N N N Low 1.5% 7-10 1-2 Y Moderate 3.0% >10 3-4 Not High Risk Y Y <-OR-> Y Moderate 3.0% >10 3-4 High Risk Y High 6.0% >=5 Not High Risk Y Y <-AND-> Y Y High [Cancer} 6.0% >=5 Not High Risk Y Y Y Y Y High 6.0% >=5 High Risk Y High 6.0% >=5 Not High Risk Y C C Y Y Cardiac Surgery w/ Uncomplicated Course Y Y <-OR-> Y Cardiac Sugery w/ Nonhemorrhagic Complication Y Y <-AND-> Y Thoracic Surgery Moderate Not High Risk Y Y <-OR-> Y High Not High Risk Y Y <-AND-> Y Y Craniotomy N N Y Very High [Cancer] Y Y <-AND-> Y Spinal Surgery N N Y High Y Y <-AND-> Y Major Trauma N Y Y <-OR-> Y High Y Y <-AND-> Y C C Y Orthopedic Surgery - THA or TKA Y Y P Y Y Y Y <-OR-> Y Orthopedic Surgery - HFS Y Y P Y Y Y <-OR-> Y Screening Aspirin VKA LMWH LDUH fondaparinux rivaroxaban Extended GCS IPC

Risk Assessment Thromboembolism Risk Caprini Score Validated primarily in surgical patients Endorsed by regional P4P collaborative for medical patients Padua Score Endorsed by ACCP Guideline 9 th Edition Bleeding Risk (NO good scoring system) IMPROVE score

VTE Prophylaxis in Hospitals Low rates of prophylaxis in US hospitals* 350,000+ high risk patients in 376 hospitals Only 36% received prophylaxis by day 2 High variability (IQR = 19-42%) Only 3% of hospitals had rate >70% Allegiance Health VTE Prophylaxis CPOE order utilization 24% in December 2010 * Rothberg et al. Venous thromboembolism prophylaxis among medical patients in US hospitals. JGIM 2010;25(6): 489-94

VTE Prophylaxis National Priority Surgeon General Call to Action in 2008 AHRQ Top Priority Joint Commission SCIP Core Measure NQF Endorsed Measures ARRA Meaningful Use Clinical Quality Measures CMS Never Event CDC Expert Panel in 2011 ACA Hospital Acquired Conditions (HAC)

VTE Prophylaxis Regional Priority Blue Cross Blue Shield Hospital Medicine Collaborative Initial Focus on VTE Prevention Developed registry for participating hospitals Incentive payments in 2013 Michigan Hospital Association Keystone Center Hospital Engagement Network Lead HHS Effort in Michigan to reduce HAC

VTE Prophylaxis Measures and Incentives VTE Measures Blue Cross Blue Shield - Hospital Medicine Safety Collaborative VTE risk screening is completed on admission High Risk patients receive pharmacological prophylaxis on admission. Note: Caprini score > = 2 is High Risk High Risk patients receive mechanical prophylaxis on admission. Note: Caprini score >= 2 is High Risk Michigan Hospital Association - Hospital Engagement Network Percent of patients with risk assessment done withing 24 hours of admission (VTE-1) Percent of at risk patients with no contraindications who receive adequate pharmacologic prophylaxis Incidence of hospital associated preventable VTEs per 100 at risk patients (VTE-2) ARRA Meaningful Use Stage 1 CQM Moderate and High Risk patients who receive VTE prophylaxis (VTE-1) Moderate and High Risk ICU patients who receive VTE prophylaxis (VTE-2) Patients with VTE who receive overlap therapy (Coumadin plus parenteral therapy) (VTE-3) VTE patients receiving unfractionated heparin with dosages/platelet count monitoring by protocol or nomogram (VTE-4) VTE warfarin therapy discharge instructions (VTE-5) % of patients who develop confirmed VTE during hospitalization who received no VTE prophlaxis prior to VTE diagnostic test order date (VTE-6) Joint Commission - SCIP Core Measures Surgery Patients with Recommended Venous Thromboembolism Prophylaxis Ordered (SCIP-VTE-1) Surgery Patients Who Received Appropriate Venous Thromboembolism Prophylaxis Within 24 Hours Prior to Surgery to 24 Hours After Surgery (SCIP-VTE-2) Patient Population Medical Medical Medical Non-ICU, Non-Surgical Non-ICU, Non-Surgical Non-ICU, Non-Surgical Medical and Surgical Medical and Surgical Patients with confirmed Patients with confirmed diagnosis of VTE Patients with confirmed Patients with confirmed diagnosis of VTE Surgical (by List of Surgeries Surgical (by List of Surgeries Performed)

Redesign of CPOE VTE Orders Risk Level Caprini Score (optional) Prophylaxis Low 0-1 Ambulation ONLY Moderate 3-4 Pharmacologic OR Mechanical High >=5 Pharmacologic AND Mechanical Additional decision support elements Choice of pharmacologic agent By weight, by renal function Contraindications harmonized among P4P initiatives Tracking orders to measure adoption Workflow elements Only show pertinent choices

Demonstrate VTE Orders

Interventions To Drive Adoption Education Memos and Medical Staff Newsletter Continuing Medical Education 1:1 Coaching High Volume Admitters Compliance Reporting (Hospitalists) Exit Reminder (Hard/Soft Stops) Pilot Group (accumulated data to justify) Expand to ALL required approval by Med Staff

Exit Reminder Providers ONLY NOT Nursing ALLOW Bypass

100.0% By Exit Reminder Pilot Group 90.0% 80.0% Exit Reminder [Pilot] 70.0% 60.0% Exit Reminder [ALL] 50.0% Compliance Report 40.0% 30.0% 20.0% 10.0% 0.0% Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2011 2012 2012 2012 2012 2012 2012 2012 2012 2012 2012 2012 2012 Y N

100.0% By Clinical Service 90.0% 80.0% 70.0% 60.0% 50.0% 40.0% 30.0% 20.0% 10.0% 0.0% Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2011 2012 2012 2012 2012 2012 2012 2012 2012 2012 2012 2012 2012 Family Practice Medicine OB-GYN Surgery

Yes No Linear (Yes) Linear (No) 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% Compliance Report Exit Reminder- Pilot Exit Reminder- ALL 0% 1-Dec 9-Dec 17-Dec 25-Dec 2-Jan 10-Jan 18-Jan 26-Jan 3-Feb 11-Feb 19-Feb 27-Feb 6-Mar 14-Mar 22-Mar 30-Mar 7-Apr 15-Apr 23-Apr 1-May 9-May 17-May 25-May 2-Jun 10-Jun 18-Jun 26-Jun 4-Jul 12-Jul 20-Jul 28-Jul 5-Aug 13-Aug 21-Aug 29-Aug 6-Sep 14-Sep 22-Sep 30-Sep 8-Oct 16-Oct 24-Oct 1-Nov 9-Nov 17-Nov 25-Nov 3-Dec 11-Dec 19-Dec 27-Dec Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2011 2012

BCBS Hospital Medicine Safety Consortium

BCBS Hospital Medicine Safety Consortium

BCBS Hospital Medicine Safety Consortium

BCBS Hospital Medicine Safety Consortium

PSI-12: Post-Op PE or DVT Facility Numerator Facility Denominator Facility Rate/1000 Peer Numerator Peer Denominator Peer Rate/1000 FY 2012 (JUL 11 - JUN 12) 7 3,799 1.84 461 106,822 4.32 FYTD 2013 (JUL 12 - AUG 12) 1 596 1.68 60 12,772 4.70

Future Direction Revisions to VTE Clinical Decision Support Alter Logic to Support: Medical vs. Surgical patients Improved Risk Stratification Make patient characteristics (i.e. egfr, current therapies ) available Alert for Epidural or other Continuous Nerve Catheter Apply Concepts to SCIP Beta-Blocker Post-Op

Thank You! jon.sykes@allegiancehealth.org

Please use blank slide if more space is required for charts, graphs, etc. To remove background graphics, right click on selected slide, choose Format Background and check Hide background graphics.